Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...

According to TipRanks.com, Lebowitz is a 4-star analyst with an average return of 4.4% and a 55.7% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Arrowhead ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic dysfunction-associated steatohepatitis/MASH in Europe.

QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund ...